Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026
Key Highlights
- ➤Q3 net revenue $207.6 million, up 8% year over year
- ➤Q3 GAAP diluted EPS $0.87, versus $0.37 in 2025
- ➤Adjusted diluted EPS $1.14, versus $0.93 year over year
- ➤Board authorized a $50 million increase to the share buyback program
- ➤BAQSIMI sales rose 10% to $58.8 million
- ➤IMS remediation pressured epinephrine sales and gross margin
Expert Statements
Dr. Jack Zhang, President and Chief Executive Officer of Amphastar Pharmaceuticals
“Our third quarter results demonstrate the strength of Amphastar's diversified portfolio and the commercial platform we have built. Record sales of BAQSIMI® and Primatene MIST®, together with contributions from recently launched products, supported continued revenue growth and further strengthened the foundation for our long-term strategy. During the quarter, we continued to advance programs across our complex generic, biosimilar, and proprietary pipelines while investing in the manufacturing, quality and development capabilities needed to support future growth. We remain focused on disciplined execution, strengthening our operations, and deploying capital in ways that we believe can create sustainable long-term value for our shareholders”
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 PR Newswire
* Net revenues of $207.6 million for the three months ended September 30, 2026 * GAAP net income of $37.8 million, or $0.87 per share, for the third quarter * Adjusted non-GAAP net income of $49.3 million, or $1.14 per share, for the third quarter * Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif., Nov. 5, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended September 30, 2026.
Get started
Create a free account to read the full story.